Yu Liu1, Feiya Du, Wei Chen, Minya Yao, Kezhen Lv, Peifen Fu. 1. Department of Breast Surgery Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China.
Abstract
BACKGROUND: Breast cancer is the major cause of cancer-related deaths in females world-wide. Doxorubicin-based therapy has limited efficacy in breast cancer due to drug resistance, which has been shown to be associated with the epithelial-to-mesenchymal transition (EMT). However, the molecular mechanisms linking the EMT and drug resistance in breast cancer cells remain unclear. Dual specificity phosphatase 4 (DUSP4), a member of the dual specificity phosphatase family, is associated with cellular proliferation and differentiation; however, its role in breast cancer progression is controversial. METHODS: We used cell viability assays, Western blotting and immunofluorescent staining, combined with siRNA interference, to evaluate chemoresistance and the EMT in MCF-7 and adriamycin-resistant MCF-7/ADR breast cancer cells, and investigate the underlying mechanisms. RESULTS: Knockdown of DUSP4 significantly increased the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin, and MCF-7/ADR cells which expressed high levels of DUSP4 had a mesenchymal phenotype. Furthermore, knockdown of DUSP4 reversed the EMT in MCF-7/ADR cells, as demonstrated by upregulation of epithelial biomarkers and downregulation of mesenchymal biomarkers, and also increased the chemosensitivity of MCF-7/ADR cells to doxorubicin. CONCLUSIONS: DUSP4 might represent a potential drug target for inhibiting drug resistance and regulating the process of the EMT during the treatment of breast cancer.
BACKGROUND:Breast cancer is the major cause of cancer-related deaths in females world-wide. Doxorubicin-based therapy has limited efficacy in breast cancer due to drug resistance, which has been shown to be associated with the epithelial-to-mesenchymal transition (EMT). However, the molecular mechanisms linking the EMT and drug resistance in breast cancer cells remain unclear. Dual specificity phosphatase 4 (DUSP4), a member of the dual specificity phosphatase family, is associated with cellular proliferation and differentiation; however, its role in breast cancer progression is controversial. METHODS: We used cell viability assays, Western blotting and immunofluorescent staining, combined with siRNA interference, to evaluate chemoresistance and the EMT in MCF-7 and adriamycin-resistant MCF-7/ADR breast cancer cells, and investigate the underlying mechanisms. RESULTS: Knockdown of DUSP4 significantly increased the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin, and MCF-7/ADR cells which expressed high levels of DUSP4 had a mesenchymal phenotype. Furthermore, knockdown of DUSP4 reversed the EMT in MCF-7/ADR cells, as demonstrated by upregulation of epithelial biomarkers and downregulation of mesenchymal biomarkers, and also increased the chemosensitivity of MCF-7/ADR cells to doxorubicin. CONCLUSIONS:DUSP4 might represent a potential drug target for inhibiting drug resistance and regulating the process of the EMT during the treatment of breast cancer.
Authors: Christian Manginstar; Andi Asadul Islam; Daniel Sampepajung; William Hamdani; Agussalim Bukhari; Salman Ardy Syamsu; Nilam Smaradania; Muhammad Faruk Journal: Ann Med Surg (Lond) Date: 2021-02-10
Authors: Jongmin Sim; Kijong Yi; Hyunsung Kim; Hyein Ahn; Yumin Chung; Abdul Rehman; Se Min Jang; Kang Hong Lee; Kiseok Jang; Seung Sam Paik Journal: Gastroenterol Res Pract Date: 2015-01-21 Impact factor: 2.260
Authors: Hyunsung Kim; Se Min Jang; Hyein Ahn; Jongmin Sim; Kijong Yi; Yumin Chung; Hulin Han; Abdul Rehman; Min Sung Chung; Kiseok Jang; Seung Sam Paik Journal: J Breast Cancer Date: 2015-03-27 Impact factor: 3.588
Authors: Tara Boulding; Fan Wu; Robert McCuaig; Jennifer Dunn; Christopher R Sutton; Kristine Hardy; Wenjuan Tu; Amanda Bullman; Desmond Yip; Jane E Dahlstrom; Sudha Rao Journal: PLoS One Date: 2016-02-09 Impact factor: 3.240
Authors: Samia Mohammed; Achraf A Shamseddine; Benjamin Newcomb; Ronald S Chavez; Tyler D Panzner; Allen H Lee; Daniel Canals; Chioma M Okeoma; Christopher J Clarke; Yusuf A Hannun Journal: Breast Cancer Res Date: 2021-07-27 Impact factor: 6.466